Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Strattera in Russian children and adolescents with ADHD
NCT00386581Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing Atomoxetine Arm with Placebo Arm (2 arms). Primary endpoint: ADHD Rating Scale IV at 6 weeks. Started Jul 2004; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00386581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00386581.